drugset / Trial / NCT03452657
Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
Phase 3
Unknown
118 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Eye & ENT Hospital of Fudan University · collabRenJi Hospital · collabShanghai 10th People's Hospital · collabShanghai Jiao Tong University Affiliated Sixth People's Hospital · collabShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · collabShanghai Tongji Hospital, Tongji University School of Medicine · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy and safety of intravitreous ranibizumab treatment versus sham injections for prevention of high-risk DR.
Timeline
- Start
- 2018-04
- Primary completion
- 2019-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |